Subcutaneous (subQ) injection is a common route for delivering biotherapeutics, wherein
pharmacokinetics is largely influenced by drug transport in a complex subQ tissue …

Despite the increasing trend towards subcutaneous delivery of monoclonal antibodies,
factors influencing the subcutaneous bioavailability of these molecules remain poorly …

Subcutaneous injections are an increasingly prevalent route of administration for delivering
biological therapies including monoclonal antibodies (mAbs). Compared with intravenous …

Subcutaneously injected formulations have been developed for many biological products
including monoclonal antibodies (mAbs). A knowledge gap nonetheless remains regarding …

Subcutaneous (SC) delivery of biologics has traditionally been limited to fluid volumes of 1–
2 mL, with recent increases to volumes of about 3 mL. This injection volume limitation poses …

The high variability in subcutaneous bioavailability of protein therapeutics is poorly
understood, contributing to critical delays in patient access to new therapies. Preclinical …

Quantitative modeling of the subcutaneous absorption processes of protein therapeutics is
challenging. Here we have proposed a “two-pore” PBPK model that is able to …

Local immunomodulation has shown the potential to control the immune response in a site-
specific manner for wound healing, cancer, allergy, and cell transplantation, thus abrogating …

Despite the growing popularity of subcutaneous (SC) administration for monoclonal
antibodies (mAbs), there remains a limited understanding of the significance of mAb …

Use of the subcutaneous (SC) route for administering monoclonal antibodies (mAbs) to treat
chronic conditions has been hindered because of an incomplete understanding of …